Caxton Corp Savara Inc Transaction History

Caxton Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$3.18 - $4.9 $9.41 Million - $14.5 Million	-2,960,161 Reduced 89.33%	353,441 $1.66 Million
Q3 2023 Nov 14, 2023	SELL	$2.97 - $3.88 $4.95 Million - $6.47 Million	-1,667,202 Reduced 33.47%	3,313,602 $12.5 Million
Q2 2023 Aug 14, 2023	SELL	$1.69 - $3.24 $3.24 Million - $6.21 Million	-1,915,747 Reduced 27.78%	4,980,804 $15.9 Million
Q1 2022 May 16, 2022	SELL	$1.05 - $1.36 $21,000 - $27,200	-20,000 Reduced 0.29%	6,896,551 $9.03 Million
Q4 2021 Feb 14, 2022	BUY	$1.04 - $1.34 $20,800 - $26,800	20,000 Added 0.29%	6,916,551 $8.58 Million
Q3 2021 Nov 15, 2021	BUY	$1.18 - $1.64 $1.12 Million - $1.55 Million	945,536 Added 15.89%	6,896,551 $9.52 Million
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.29 $300,188 - $455,252	198,800 Added 3.46%	5,951,015 $10.1 Million
Q1 2021 May 17, 2021	BUY	$1.17 - $2.33 $6.73 Million - $13.4 Million	5,752,215 New	5,752,215 $12 Million

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.